Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Nhwa to Distribute Teva’s Movement Disorder Therapies in China

publication date: Feb 27, 2024

Jiangsu Nhwa Pharma formed a China partnership to distribute a Teva Pharma therapy that treats two neurodegenerative and movement disorders - chorea associated with Huntington’s disease and tardive dyskinesia in adults. Teva’s Austedo is the only vesicular monoamine transporter 2 inhibitor approved by the US FDA for adults with either condition. Austedo, a deuterated drug, replaces hydrogen atoms with deuterium, which is expected to lower metabolism rates and facilitate less frequent dosing. Nhwa’s focus is on providing new therapies for China’s neuro-psychiatric health sector. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here